AVITA Medical (NASDAQ:RCEL - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.47), Zacks reports. The firm had revenue of $11.10 million during the quarter, compared to analysts' expectations of $11.08 million. AVITA Medical had a negative net margin of 88.41% and a negative return on equity of 74.42%. During the same quarter in the prior year, the firm posted ($0.37) EPS. AVITA Medical updated its Q2 2024 guidance to EPS.
AVITA Medical Stock Down 6.0 %
Shares of NASDAQ RCEL traded down $0.52 during mid-day trading on Wednesday, reaching $8.20. 329,075 shares of the company traded hands, compared to its average volume of 218,705. The company has a debt-to-equity ratio of 0.81, a quick ratio of 7.46 and a current ratio of 7.88. The stock has a market cap of $211.56 million, a PE ratio of -4.66 and a beta of 1.42. The company's fifty day moving average is $12.42 and its two-hundred day moving average is $13.47. AVITA Medical has a fifty-two week low of $7.51 and a fifty-two week high of $21.70.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. BTIG Research downgraded AVITA Medical from a "buy" rating to a "neutral" rating in a research report on Thursday, April 11th. Cantor Fitzgerald dropped their target price on AVITA Medical from $22.00 to $21.00 and set an "overweight" rating on the stock in a report on Tuesday. Finally, Piper Sandler restated a "neutral" rating and set a $9.00 price objective (down previously from $21.00) on shares of AVITA Medical in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.60.
View Our Latest Stock Analysis on AVITA Medical
About AVITA Medical
(
Get Free Report)
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
Read More
Before you consider AVITA Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVITA Medical wasn't on the list.
While AVITA Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
